Evaluation of ¹²⁵I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery

Objective: To investigate the clinical value of ¹²⁵I radioactive seed interstitial implantation in the treatment of advanced pancreatic cancer. Methods The pain classification, solid tumor response evaluation criteria, and tumor markers(carbohydrate antigen CA242 and CA19-9) were examined in 97 patients with advanced pancreatic cancer by using ultrasound-guided ¹²⁵I particle implantation surgery to evaluate the complications and adverse reactions of the tool. Results: Comparison among preoperative state, 1 week, 2 weeks, 1 month and 3 months post-surgery revealed significant differences in pain scores(χ² = 0.018, 0.022, 0.034, 0.045, all P < 0.05); 8 cases had complete remission, 46 cases had partial remission, 34 cases were stable, and 9 cases progressed. The total effectiveness rate was 55.67%(54/97); moreover, comparison among the preoperative state, 1 month, and 3 months post-surgery indicated significant differences in the serum levels of CA19-9 and CA242(χ² = 0.027, 0.029, 0.017, 0.022, all P < 0.05). After treatment, the median survival time was(8.0 ± 4.5) months. No serious complications and adverse reactions were observed. Conclusion: ¹²⁵I radioactive particle implantation for the treatment of advanced pancreatic cancer using ultrasound-guided surgery had curative effects, high safety, and significant pain relief. (authors)